Clinical characterization of common pathogenic variants of SOD1-ALS in Germany
-
Published:2024-08-14
Issue:
Volume:
Page:
-
ISSN:0340-5354
-
Container-title:Journal of Neurology
-
language:en
-
Short-container-title:J Neurol
Author:
Wiesenfarth MaximilianORCID, Forouhideh-Wiesenfarth Yalda, Elmas Zeynep, Parlak Özlem, Weiland Ulrike, Herrmann Christine, Schuster Joachim, Freischmidt Axel, Müller Kathrin, Siebert Reiner, Günther Kornelia, Fröhlich Elke, Knehr Antje, Simak Tatiana, Bachhuber Franziska, Regensburger Martin, Petri Susanne, Klopstock Thomas, Reilich Peter, Schöberl Florian, Schumann Peggy, Körtvélyessy Peter, Meyer Thomas, Ruf Wolfgang P., Witzel Simon, Tumani Hayrettin, Brenner David, Dorst Johannes, Ludolph Albert C.
Abstract
AbstractPathogenic variants in the Cu/Zn superoxide dismutase (SOD1) gene can be detected in approximately 2% of sporadic and 11% of familial amyotrophic lateral sclerosis (ALS) patients in Europe. We analyzed the clinical phenotypes of 83 SOD1-ALS patients focusing on patients carrying the most frequent (likely) pathogenic variants (R116G, D91A, L145F) in Germany. Moreover, we describe the effect of tofersen treatment on ten patients carrying these variants. R116G patients showed the most aggressive course of disease with a median survival of 22.0 months compared to 198.0 months in D91A and 87.0 months in L145F patients (HR 7.71, 95% CI 2.89–20.58 vs. D91A; p < 0.001 and HR 4.25, 95% CI 1.55–11.67 vs. L145F; p = 0.02). Moreover, R116G patients had the fastest median ALSFRS-R progression rate with 0.12 (IQR 0.07–0.20) points lost per month. Median diagnostic delay was 10.0 months (IQR 5.5–11.5) and therefore shorter compared to 57.5 months (IQR 14.0–83.0) in D91A (p < 0.001) and 21.5 months (IQR 5.8–38.8) in L145F (p = 0.21) carriers. As opposed to D91A carriers (50.0%), 96.2% of R116G (p < 0.001) and 100.0% of L145F (p = 0.04) patients reported a positive family history. During tofersen treatment, all patients showed a reduction of neurofilament light chain (NfL) serum levels, independent of the SOD1 variant. Patients with SOD1-ALS carrying R116G, D91A, or L145F variants show commonalities, but also differences in their clinical phenotype, including a faster progression rate with shorter survival in R116G, and a comparatively benign disease course in D91A carriers.
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O’Regan JP, Deng HX et al (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59–62. https://doi.org/10.1038/362059a0 2. Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27:1918–1929. https://doi.org/10.1111/ene.14393 3. Chiò A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS Study Group (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82:740–746. https://doi.org/10.1136/jnnp.2010.235952 4. Rosenbohm A, Peter RS, Erhardt S, Lulé D, Rothenbacher D, Ludolph AC, Nagel G, ALS Registry Study Group (2017) Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol 264:749–757. https://doi.org/10.1007/s00415-017-8413-3 5. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245–256. https://doi.org/10.1016/j.neuron.2011.09.011
|
|